Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ticagrelor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 known ✓ | Q9H244 | 16/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | FPR3 | P25089 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | P2RY13 | Q9BPV8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticagrelor SCHEMBL2612402 | 1.00 | P2RY12 (1.00) | P2RY12PGRADORA3CHRM1DRD1 | |
| Ticagrelor SCHEMBL16296587 | 1.00 | P2RY12 (1.00) | P2RY12PGRADORA3CHRM1DRD1 | |
| Ticagrelor SCHEMBL17679491 | 1.00 | P2RY12 (1.00) | P2RY12PGRADORA3CHRM1DRD1 | |
| Ticagrelor SCHEMBL20208100 | 1.00 | P2RY12 (1.00) | P2RY12PGRADORA3CHRM1DRD1 | |
| Ticagrelor SCHEMBL14566034 | 1.00 | P2RY12 (1.00) | P2RY12PGRADORA3CHRM1DRD1 | |
| Ticagrelor SCHEMBL24418222 | 1.00 | P2RY12 (1.00) | P2RY12PGRADORA3CHRM1DRD1 | |
| Ticagrelor SCHEMBL17679477 | 1.00 | P2RY12 (1.00) | P2RY12PGRADORA3CHRM1DRD1 | |
| Ticagrelor SCHEMBL22375060 | 1.00 | P2RY12 (1.00) | P2RY12PGRADORA3CHRM1DRD1 | |
| Ticagrelor SCHEMBL20866157 | 1.00 | P2RY12 (1.00) | P2RY12PGRADORA3CHRM1DRD1 | |
| Ticagrelor SCHEMBL18674056 | 1.00 | P2RY12 (1.00) | P2RY12PGRADORA3CHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604991-B2 | Preparation method of ticagrelor and intermediates thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-28 | — | — | US | disclosed |
| US-20160102101-A1 | Preparation method of Ticagrelor and intermediates thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2016-04-14 | — | — | US | disclosed |
| EP-2340252-B1 | A PROCESS FOR PREPARING [1S- ]1-ALPHA, 2-ALPHA, 3-BETA (1S*, 2R*) 5-BETA] ]-3- [7- [2- (3, 4-DIF LUOROPHENYL) -CYCLOPROPYLAMINO]- 5- (PROPYLTHIO) -3H-1, 2, 3-TRIAZOLO [4, 5-D]PYRIMIDIN-3-YL]-5- (2- HYDROXYETHOXY) CYCLOPENTANE-1, 2-DIOL AND TO ITS INTERMEDIATES | ASTRAZENECA AB (SE) | 2015-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102101-A1 | Preparation method of Ticagrelor and intermediates thereof | TPMT, NUDT1, ITPA | P2RY12 66/4885PGR 1972/4885ADORA3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.